Investigational TKI Shows Promise For Treating Castration-Resistant Prostate Cancer

Although its still in trials and approval takes quite a while, here's some good news. Investigational TKI Shows Promise For Treating Castration-Resistant Prostate Cancer. MedPage Today (6/9, Bankhead) reported that two-thirds of men with "castration-resistant prostate cancer (CRPC) had clinical benefit when treated with an investigational multitargeted tyrosine kinase inhibitor (TKI)," according to findings presented at the American Society for Clinical Oncology meeting. Data from a randomized trial showed that between "two-thirds and three-fourths of patients had measurable disease regression, complete or partial resolution of bone lesions, and improvement in pain." The patients had a "median progression-free survival (PFS) of 29 weeks, which included a threefold improvement in PFS in a small group of patients randomized to cabozantinib or placebo. 'In patients with progressive metastatic castration-resistant prostate cancer, cabozantinib has substantial antitumor activity,'" noted the lead study author.